Regorafenib for cancer

Explaining the Unexplainable: EGFR Antibodies in Colorectal Cancer

(2012) Axel Grothey et al.   JOURNAL OF CLINICAL ONCOLOGY

Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies

(2012) James P. B. O'Connor et al.   Nature Reviews Clinical Oncology

7141 POSTER Phase II Trial of the Oral Multikinase Inhibitor Regorafenib (BAY 73-4506) as First-line Therapy in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)

(2011) T. Eisen et al.   EUROPEAN JOURNAL OF CANCER

Protocol Information Provides Opportunity for Patient Safety and Quality Improvement

(2011) Thomas J. George et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential Properties of Current Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors

(2011) George D. Demetri   SEMINARS IN ONCOLOGY

Experience with sorafenib and adverse event management

(2010) Joaquim Bellmunt et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

(2010) Scott M. Wilhelm et al.   INTERNATIONAL JOURNAL OF CANCER

Cyclophosphamide, Vincristine, and Prednisone Followed by Tositumomab and Iodine-131–Tositumomab in Patients With Untreated Low-Grade Follicular Lymphoma: Eight-Year Follow-Up of a Multicenter Phase II Study

(2010) Brian K. Link et al.   JOURNAL OF CLINICAL ONCOLOGY

Personalized Medicine in Non–Small-Cell Lung Cancer: IsKRASa Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?

(2010) Patrick J. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

PharmaForum

(2010)   ONKOLOGIE

Renal Effects of Anti-angiogenesis Therapy: Update for the Internist

(2009) Faina Gurevich et al.   AMERICAN JOURNAL OF MEDICINE

Management of hypertension in angiogenesis inhibitor-treated patients

(2009) H. Izzedine et al.   ANNALS OF ONCOLOGY

7105 Phase II trial of the oral multikinase inhibitor BAY 73–4506 as 1st-line therapy in patients with metastatic or unresectable renal cell cancer (RCC)

(2009) T. Eisen et al.   EJC SUPPLEMENTS

VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management

(2009) Hassane Izzedine et al.   EUROPEAN JOURNAL OF CANCER

Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial

(2009) Merrill S. Kies et al.   JOURNAL OF CLINICAL ONCOLOGY

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy

(2009) Francesco Torino et al.   Nature Reviews Clinical Oncology

Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib

(2009) Adam D. Lipworth et al.   ONCOLOGY

Histologic Results of Para-Aortic Lymphadenectomy in Patients Treated for Stage IB2/II Cervical Cancer With Negative [18F]Fluorodeoxyglucose Positron Emission Tomography Scans in the Para-Aortic Area

(2008) Mathias Boughanim et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE